» Articles » PMID: 36271556

EMT Mechanism in Breast Cancer Metastasis and Drug Resistance: Revisiting Molecular Interactions and Biological Functions

Abstract

One of the malignant tumors in women that has involved both developed and developing countries is breast cancer. Similar to other types of tumors, breast cancer cells demonstrate high metastatic nature. Besides, breast tumor cells have ability of developing drug resistance. EMT is the related mechanism to cancer metastasis and focus of current manuscript is highlighting function of EMT in breast tumor malignancy and drug resistance. Breast tumor cells increase their migration by EMT induction During EMT, N-cadherin and vimentin levels increase, and E-cadherin levels decrease to mediate EMT-induced breast tumor invasion. Different kinds of anti-cancer agents such as tamoxifen, cisplatin and paclitaxel that EMT induction mediates chemoresistance feature of breast tumor cells. Furthermore, EMT induction correlates with radio-resistance in breast tumor. Clinical aspect is reversing EMT in preventing chemotherapy or radiotherapy failure in breast cancer patients and improving their survival time. The anti-tumor agents that suppress EMT can be used for decreasing breast cancer invasion and increasing chemosensitivity of tumor cells. Furthermore, lncRNAs, miRNAs and other factors can modulate EMT in breast tumor progression that are discussed here.

Citing Articles

TNBC response to paclitaxel phenocopies interferon response which reveals cell cycle-associated resistance mechanisms.

Calistri N, Liby T, Hu Z, Zhang H, Dane M, Gross S Sci Rep. 2025; 15(1):4294.

PMID: 39905117 PMC: 11794704. DOI: 10.1038/s41598-024-82218-9.


EFHD1 Activates SIK3 to Limit Colorectal Cancer Initiation and Progression via the Hippo Pathway.

Huang Q, Tang X, Gan C, Deng Q, Zhi S, Huang Q J Cancer. 2025; 16(4):1348-1362.

PMID: 39895792 PMC: 11786025. DOI: 10.7150/jca.103229.


Triptolide reverses cis‑diamminedichloroplatinum resistance in esophageal squamous cell carcinoma by suppressing glycolysis and causing mitochondrial malfunction.

Liu K, Liu J, Meng T, Wu N, Liu J, Qiao M Mol Med Rep. 2025; 31(3).

PMID: 39886972 PMC: 11795233. DOI: 10.3892/mmr.2025.13439.


Implications of Mineralization Biomarkers in Breast Cancer Outcomes Beyond Calcifications.

Giacobbi E, Bonfiglio R, Rotondaro G, Servadei F, Smirnov A, Palumbo V Int J Mol Sci. 2025; 26(2).

PMID: 39859358 PMC: 11765781. DOI: 10.3390/ijms26020645.


Exploring vimentin's role in breast cancer via PICK1 alternative polyadenylation and the miR-615-3p-PICK1 interaction.

Jia X, Shao L, Quan H, Zhong Z, Dong C Biofactors. 2025; 51(1):e2147.

PMID: 39781570 PMC: 11712540. DOI: 10.1002/biof.2147.